BACKGROUND: Canada's publicly funded blood system has recently introduced high-purity concentrates as the standard treatment for individuals with hemophilia. The added cost and the need to document patient outcomes have prompted the consideration of a national blood product monitoring system. STUDY DESIGN AND METHODS: This study investigates the suitability of the Canadian Hemophilia Registry (CHR) as the basis of such a monitoring system by assessing the degree to which it represents users of factor concentrates. RESULTS: Currently, there are 1978 individuals registered with the CHR, of whom 1594 (81%) have hemophilia A and 384 (19%) have hemophilia B. The total prevalence is 7.2 per 10(5) population, with the prevalence of severe cases being 2.3 per 10(5). This overall prevalence is similar to that seen in other countries with national registries. The CHR national prevalence also compares favorably with that in the province of Quebec, where registration of users of blood products is compulsory. The CHR figures indicate that the number of persons currently infected with human immunodeficiency virus, both alive and dead, is 652, which is similar to the number of applicants (658) to the federal government's assistance program. The registry is stable, and the number of persons with severe cases, other than young children, newly registered or lost to follow-up during the last 2 years is very small. CONCLUSION: The CHR includes the vast majority of factor concentrate users and is therefore ideal as the basis for a national monitoring system.
BACKGROUND: Canada's publicly funded blood system has recently introduced high-purity concentrates as the standard treatment for individuals with hemophilia. The added cost and the need to document patient outcomes have prompted the consideration of a national blood product monitoring system. STUDY DESIGN AND METHODS: This study investigates the suitability of the Canadian Hemophilia Registry (CHR) as the basis of such a monitoring system by assessing the degree to which it represents users of factor concentrates. RESULTS: Currently, there are 1978 individuals registered with the CHR, of whom 1594 (81%) have hemophilia A and 384 (19%) have hemophilia B. The total prevalence is 7.2 per 10(5) population, with the prevalence of severe cases being 2.3 per 10(5). This overall prevalence is similar to that seen in other countries with national registries. The CHR national prevalence also compares favorably with that in the province of Quebec, where registration of users of blood products is compulsory. The CHR figures indicate that the number of persons currently infected with human immunodeficiency virus, both alive and dead, is 652, which is similar to the number of applicants (658) to the federal government's assistance program. The registry is stable, and the number of persons with severe cases, other than young children, newly registered or lost to follow-up during the last 2 years is very small. CONCLUSION: The CHR includes the vast majority of factor concentrate users and is therefore ideal as the basis for a national monitoring system.
Authors: Claudia Pamela Radic; Liliana Carmen Rossetti; Miguel Martín Abelleyro; Miguel Candela; Raúl Pérez Bianco; Miguel de Tezanos Pinto; Irene Beatriz Larripa; Anne Goodeve; Carlos Daniel De Brasi Journal: Thromb Haemost Date: 2012-10-23 Impact factor: 5.249
Authors: Tarek Owaidah; Abdulkareem Al Momen; Hazzaa Alzahrani; Abdulrahman Almusa; Fawaz Alkasim; Ahmed Tarawah; Randa Al Nouno; Fatima Al Batniji; Fahad Alothman; Ali Alomari; Saud Abu-Herbish; Mahmoud Abu-Riash; Khawar Siddiqui; Mansor Ahmed; S Y Mohamed; Mahasen Saleh Journal: Medicine (Baltimore) Date: 2017-01 Impact factor: 1.889
Authors: A N Traore; A K C Chan; K E Webert; N Heddle; B Ritchie; J St-Louis; J Teitel; D Lillicrap; A Iorio; I Walker Journal: Haemophilia Date: 2014-07 Impact factor: 4.287
Authors: Suely Meireles Rezende; Silvia Helena Lacerda Rodrigues; Kelly Neves Pinheiro Brito; Diego Lima Quintino da Silva; Marcos Lázaro Santo; Bárbara de Jesus Simões; Guilherme Genovez; Helder Teixeira Melo; João Paulo Baccara Araújo; Danila Augusta Accioly Varella Barca Journal: Orphanet J Rare Dis Date: 2017-02-10 Impact factor: 4.123